TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $11.00 Average PT from Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has earned a consensus rating of “Hold” from the four research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $11.00.

Several brokerages have commented on TLSI. Wall Street Zen downgraded shares of TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Zacks Research upgraded shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. Canaccord Genuity Group raised their target price on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th.

TriSalus Life Sciences Trading Down 0.9%

TriSalus Life Sciences stock opened at $5.44 on Friday. The business’s 50 day simple moving average is $6.34 and its 200 day simple moving average is $5.25. TriSalus Life Sciences has a 12 month low of $3.42 and a 12 month high of $7.95. The company has a market cap of $271.78 million, a price-to-earnings ratio of -2.69 and a beta of 0.43.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.79). The business had revenue of $11.57 million for the quarter, compared to analysts’ expectations of $11.76 million. As a group, equities research analysts forecast that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC increased its stake in shares of TriSalus Life Sciences by 2.0% in the third quarter. Nantahala Capital Management LLC now owns 2,040,245 shares of the company’s stock worth $9,487,000 after buying an additional 40,245 shares during the period. Millennium Management LLC grew its holdings in TriSalus Life Sciences by 17.7% in the 3rd quarter. Millennium Management LLC now owns 35,612 shares of the company’s stock worth $166,000 after acquiring an additional 5,359 shares during the last quarter. Squarepoint Ops LLC bought a new stake in TriSalus Life Sciences in the 3rd quarter worth $343,000. White Pine Capital LLC purchased a new position in shares of TriSalus Life Sciences in the third quarter valued at about $278,000. Finally, Vanguard Group Inc. raised its stake in shares of TriSalus Life Sciences by 42.4% during the third quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after acquiring an additional 345,186 shares during the last quarter. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.